Eric Karran, Foundational Neuroscience Center, Cambridge, Boston, USA

Eric Karran

Eric H Karran PhD is a molecular biochemist by training. He is currently at AbbVie where he is Vice President and Site Head of the Foundational Neuroscience Center in Cambridge, Boston. Eric previously was the Director of Research for Alzheimer’s Research UK. He had responsibility for the organisation’s strategic scientific direction. Eric launched the Drug Discovery Alliance, a collaboration between Medical Research Charity−Technology, Astex, Eisai , Eli Lilly, Merck, and AbbVie, placing three Drug Discovery Institutes in the Universities of Oxford and Cambridge, University College London, and the Dementia Consortium to perform validation and lead generation studies on novel targets for neurodegenerative diseases. Eric has spent most of his career in the pharmaceutical industry, leading and managing multi-disciplinary drug discovery teams. He has held senior positions in a number of companies, including SmithKline Beecham (now GSK), Pfizer, Eli Lilly, and at Johnson and Johnson. Eric has specialised in neuroscience research, particularly Alzheimer’s disease and cognitive impairment, for the past 20 years. During his career Eric has led teams that have put a number of drugs into clinical development. Eric is a visiting professor in the department for human genetics at the Catholic University of Leuven, Belgium; an honorary senior research associate in the department of molecular neuroscience at the Institute of Neurology, University College London; and a visiting professor of neurodegenerative diseases at the University of Lincoln, UK.

« Go Back

Supporting Publication
Organised by
  • Lancet Neurology
  • Elsevier
Silver Sponsor